Redeye initiates coverage of Cyxone, a Swedish biotech developing disease-modifying drugs for Rheumatoid Arthritis (RA) and Multiple Sclerosis (MS), as well as a treatment for Covid-19. An experienced management team, a de-risked lead candidate and undemanding valuation underpin our interest in the case.